| Title |
Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, November 2006
|
| DOI | 10.1007/s10549-006-9430-6 |
| Pubmed ID | |
| Authors |
Hope Rugo, Emma Shtivelman, Alejandra Perez, Charles Vogel, Sandra Franco, Elizabeth Tan Chiu, Michelle Melisko, Mary Tagliaferri, Isaac Cohen, Mark Shoemaker, Zung Tran, Debu Tripathy |
| Abstract |
Botanical therapies are often used by breast cancer patients yet few clinical trials have evaluated their safety and efficacy. We studied mechanisms of activity and performed a phase I clinical trial in patients with advanced breast cancer to evaluate BZL101, an aqueous extract from Scutellaria barbata. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Norway | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 3% |
| Unknown | 28 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 34% |
| Student > Master | 4 | 14% |
| Student > Ph. D. Student | 4 | 14% |
| Student > Postgraduate | 2 | 7% |
| Student > Bachelor | 2 | 7% |
| Other | 1 | 3% |
| Unknown | 6 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 6 | 21% |
| Medicine and Dentistry | 5 | 17% |
| Nursing and Health Professions | 3 | 10% |
| Biochemistry, Genetics and Molecular Biology | 2 | 7% |
| Psychology | 2 | 7% |
| Other | 3 | 10% |
| Unknown | 8 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 September 2016.
All research outputs
#2,918,113
of 22,659,164 outputs
Outputs from Breast Cancer Research and Treatment
#451
of 4,612 outputs
Outputs of similar age
#10,816
of 152,861 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#3
of 26 outputs
Altmetric has tracked 22,659,164 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,612 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 152,861 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 26 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.